[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

Ida Wong-SefidanDepartment of Haematology/Oncology, Moores Cancer Center, University of California, San Diego, CA, USA; Correspondence[email protected]

Michelle ByrtekStatistics, Genentech Inc., South San Francisco, CA, USA;

Xiaolei ZhouBiostatistics, RTI Health Solutions, Research Triangle Park, NC, USA;

Jonathan W. FriedbergSchool of Medicine and Dentistry, University of Rochester, Rochester, NY, USA;

Christopher R. FlowersWinship Cancer Institute, Emory University, Atlanta, GA, USA;

Andrew D. ZelenetzDepartment of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

Keith L. DawsonMedical Affairs, Genentech Inc., South San Francisco, CA, USA

Erin ReidDepartment of Haematology/Oncology, Moores Cancer Center, University of California, San Diego, CA, USA;

show all

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date